Orgenesis has filed a patent for a composition that includes ribonucleases and bioxomes, exosomes, or a combination of both. The composition is intended for the treatment and prevention of viral diseases, including Covid-19. The patent also covers the use of immune cells and ribonucleases in the formulation for treating the disease. GlobalData’s report on Orgenesis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Orgenesis Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Orgenesis, NSAID cancer drugs was a key innovation area identified from patents. Orgenesis's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment for viral diseases using ribonucleases and bioxomes/exosomes